Reform Otc Derivatives
Reform Otc Derivatives
Reforming OTC
Derivative Markets
A UK perspective
December 2009
Contents
1 Executive Summary 3
2 Introduction 5
3 Standardisation: Definition, benefits and challenges 8
4 Greater use of central counterparty (CCP) clearing 11
5 Strengthening risk management for non-cleared trades 16
6 The role of capital 19
7 Greater transparency 22
8 The role of organised trading platforms 29
9 Position limits 31
10 Conclusions 36
1.2 In summary, the Treasury and the FSA (‘UK Authorities’) propose that the following
measures need to be implemented and/or developed to address systemic shortcomings
in OTC derivative markets:
• More robust counterparty risk management. All OTC derivative trades, whether
or not centrally cleared, should be subject to robust arrangements to mitigate
counterparty risk. For all financial firms this should be through the use of CCP
clearing for clearing eligible products. For trades which are not centrally cleared
these should be subject to robust bilateral collateralisation arrangements and
appropriate risk capital requirements. This approach may differ for non-financial
firms given the different nature of the risks they pose to the financial system.
It is important that all participants bear the cost of managing the risk they pose.
• International agreement as to which products are ‘clearing eligible’. This will require
assessment by both regulators and CCPs in deciding which products are eligible
for clearing. In addition to the degree of standardisation, consideration must also
be given to the regular availability of prices; the depth of market liquidity; and
whether the product contains any inherent risk attributes that cannot be mitigated
by the CCP. Once clearing eligible products are identified, regulators should set
challenging targets for CCP usage with active monitoring of progress against
these rather than mandate the use of CCP clearing.
• Capital charges to reflect appropriately the risks posed to the financial system.
These should be higher for non-centrally cleared trades and we are working
through the Basel Committee to deliver a proportionate approach. Capital
charges for exposures to CCPs should also be risk-based.
• Registration of all relevant OTC derivative trades in a trade repository. This will
facilitate regulators having appropriate access to the information they need to fulfil
their regulatory responsibilities. We are working through the OTC Derivative
Regulators Forum (ORF) to deliver this across a number of asset classes.
• On-exchange trading. Once these steps have been taken we do not see at this
stage the need for mandating the trading of standardised derivatives on organised
trading platforms. Regulatory objectives of reducing counterparty risk and
improving transparency can be achieved by other means and we will review
progress of initiatives in this area. Moreover, mandating the use of organised
platforms would imply a regulatory imposition of trading structure, which we
do not believe is necessary.
1.3 This paper sets out our detailed thinking on each of these key issues as well as
outlining our approach for taking these measures forward.
2.1 The financial crisis revealed shortcomings in the management of counterparty credit
risk and the absence of sufficient transparency in OTC derivatives markets. Given the
importance of OTC markets to the UK economy (43% of the global OTC market is
located in the UK)1 the UK has been leading the analysis of how these issues might
be addressed.
I) Counterparty risk
2.2 The default, or fear of default, of a major market participant can have systemic
implications, due to the web of relationships between market participants. The default
by one party can have a domino effect as the credit worthiness of non-defaulting
counterparties is affected. These concerns were experienced throughout the crisis
e.g. by market concerns over the solvency of Bear Stearns which resulted in derivative
counterparties being highly sensitive to each other’s credit risk and the withdrawal
of credit lines. As large financial institutions are the main participants in OTC markets
the impact in other markets was significant.
2.3 AIG highlighted weaknesses in the management of counterparty risk for bespoke, and
therefore less clearable, OTC derivatives. Many of AIG’s counterparties had agreed to
only require collateral to cover AIG’s counterparty risk if AIG were downgraded. When
AIG did experience difficulties simultaneous collateral calls and a liquidity squeeze at
AIG resulted in its eventual bail-out to avoid systemic repercussions.
1 www.ifsl.org.uk/upload/CBS_Derivatives_2007.pdf
2 The EC’s 07/2009 paper “Ensuring efficient, safe and sound derivatives markets” explains that the opaqueness of the
market prevented market participants from knowing exactly what the exposures of their counterparties were to AIG,
Lehman’s and Bear Sterns resulting in mistrust and the drying up of liquidity in the inter-bank money market.
2.7 This paper sets out our detailed thinking on the shape of the regulatory landscape for
OTC derivative markets going forward. As the paper outlines, we share the objectives
of legislators in both the EU and the US, and we welcome the broad thrust of proposals
under discussion. We welcome the opportunity to work closely with our European
and international counterparts to ensure that a robust and transparent regime that
limits the scope for regulatory arbitrage is introduced. However, we do see some
important differences in emphasis between the current proposals and our thinking.
We believe some of the measures that have been proposed could have potentially
damaging impacts on financial markets. This paper outlines some of our concerns.
• why the current bilateral collateralisation model needs enhancing and how we
are leading work in this area;
• our approach to supporting more transparent markets, both for regulators and
for the market;
• how regulatory objectives can be achieved without forcing trade flow through
organised trading platforms; and
3 The Treasury and the FSA provided a joint and public response to the consultation
http://www.fsa.gov.uk/pubs/international/response_derivatives.pdf
4 The September 2009 communiqué states: ‘All standardised OTC derivative contracts should be traded on exchanges
or electronic trading platforms, where appropriate, and cleared through central counterparties by end-2012 at the
latest. OTC derivative contracts should be reported to trade repositories. Non-centrally cleared contracts should be
subject to higher capital requirements. We ask the FSB and its relevant members to assess regularly implementation
and whether it is sufficient to improve transparency in the derivatives markets, mitigate systemic risk, and protect
against market abuse.’
Greater use of CCP clearing for OTC derivatives – The UK Authorities have been
involved in securing commitments from major derivatives dealers to increase the use
of CCP clearing and good progress is being made against meeting these targets.5
Minimum standards for CCPs – The FSA has also been working as a member of the
Committee on Payment and Settlement Systems and the International Organisation of
Securities Commissions (CPSS-IOSCO) to review existing standards for CCPs in order
to better address risks associated with clearing OTC derivatives. And the Financial
Stability Board has included this work within its own work programme to reduce the
moral hazard posed by systemically-important financial institutions.
5 http://www.ny.frb.org/newsevents/news/markets/2009/ma090908c.pdf
The issue
3.1 The diversity of OTC derivative products means they can range from highly standardised
to bespoke and complex. When a high volume product is not standardised, it limits the
extent to which existing market infrastructure and transparency can be used effectively.
This can lead to inefficiencies in price discovery, in the valuation of positions and low use
of post-trade operational processes.
3.3 In aggregate these market developments would allow participants to trade, settle
and monitor positions in a more straightforward way and it could encourage the
use, where feasible, of simpler derivatives thereby reducing unnecessary complexity
and facilitating more robust risk management.
3.6 A significant amount of the legislative debate has focussed on using the term
‘standardised’ to categorise which products must be traded on exchange and/or
cleared via a CCP. However, there are benefits from pursing greater standardisation
in itself, irrespective of whether these products are then cleared or traded on an
exchange. We support this wider approach to setting universal standards. This may
result in products which may be considered to be standardised but are still not
suitable for CCP clearing as they do not meet other necessary criteria.
3.7 However, standardisation will mean little if definitions and practices are applied
in one jurisdiction and not another. In order to maximise the possible benefits from
standardisation, it is essential that an international agreement between regulators
and market participants is reached as to what standardisation means and what is
realistically achievable on an asset class by asset class basis. Regulators alone are
not equipped to make these decisions.
Progress to date
3.8 Considerable work has already been undertaken by industry, some of which was
driven by the regulatory push for increased use of clearing, under the auspices of
ISDA, with oversight by the international group of derivative supervisors. Focus
has been on identifying and implementing changes that will bring about increased
standardisation in each of the OTC derivative asset classes. Examples include:
• The launch of the Small and Big Bang Protocols for the credit derivatives; and
3.9 Further standardisation is likely to require progress from industry in several areas
including underlying definitions, confirmation templates and market practices with
regards to post-trade and lifecycle events. Once achieved these will support the overall
goal of straight through processing.
3.12 Where suitable levels of standardisation already exist, we will be requiring industry to
commit to challenging targets for post-trade processes in order to achieve the objective
of trade date straight-through processing for the majority of such trades. We will
require firms to dedicate sufficient resources to meet existing targets and establish
increasingly aggressive targets for continued development.
The issue
4.1 An acute sensitivity to counterparty risk, particularly at the height of the crisis, had
severe implications for financial markets and resulted in the retraction in liquidity as
participants became reluctant to trade with each other. This, in turn, was exacerbated
by the significant web of interconnections between counterparties, and led to further
negative consequences as participants could not properly access financial markets.
Regulatory solution
4.2 The increased use of CCP clearing for an internationally defined set of ‘clearing eligible’
products is a key step in mitigating this risk. A CCP can impose consistent and robust
risk management practices as well as act as a circuit breaker to the default of a member.
In addition, greater use of CCP clearing can aid market liquidity and efficiency, be a
motivating force behind contract standardisation, and reduce systemic risk.
4.3 The September 2009 G20 communiqué called for ‘all standardised OTC derivative
contracts to be cleared through central counterparties by end 2012 at the latest’. The
UK Authorities strongly support the greater use of CCP clearing arrangements in OTC
derivative markets for products which are ‘clearing-eligible’. Furthermore, the UK
Authorities agree that challenging interim targets should be set for the industry to
meet ahead of the 2012 G20 deadline.
• whether the product contains inherent risk attributes that can not be mitigated
by the CCP.
4.6 Using this combination of factors would enable CCPs to more effectively risk manage
the exposures both in terms of calculating appropriate margin calls, and in unwinding
positions in the event of a default of one of their members.
4.7 These determining factors should be supported by the appropriate processes for
agreeing which products are ‘clearing eligible’. In our view this should include
regulators working with the relevant market participants to decide which products
are clearing eligible. However, CCPs should not be forced to clear a product if they
are unable to manage the risk of doing so. Equally, regulators should have the ability
to decide a product is not clearing eligible if they are not comfortable with the risk
management processes available in CCPs.
4.8 It is for these reasons that we do not support proposals to mandate CCP clearing for all
standardised derivatives. Mandating the clearing of all standardised derivatives could
lead to a situation where a CCP is required to clear a product that it is not able to risk
manage adequately, with the potential for serious difficulties in the event of a default.
4.9 Furthermore whilst we support the use of ambitious and challenging targets for CCP
usage for clearing eligible products with close regulatory oversight we do not believe
this should be mandatory. For example, there may be some circumstances in which the
more appropriate risk management approach is to manage a clearing eligible position
alongside a non-clearing eligible position with the same counterparty outside of the
clearing house. We also recognise the costs and difficulties that certain market
participants may have in accessing CCP clearing, and the impact mandating central
clearing could have on them.
4.11 There are currently three clearing houses that are actively clearing CDS products
with others expected to launch services shortly. In addition there are plans to expand
product coverage which will mean that a greater proportion of credit derivatives
business over time will become eligible for CCP clearing. Supervisors will require the
clearing target levels agreed with the OTC Derivatives Supervisors Group to be
updated to reflect the expansion of product sets.
6 http://www.ny.frb.org/newsevents/news/markets/2009/ma090908c.pdf
4.15 The UK Authorities agree that all market participants should have access to the benefits
of CCP clearing for ‘clearing eligible’ OTC derivatives, including those participants
who are not clearing members themselves. We consider that the availability of
segregation and portability facilities would further encourage CCP use and bring other
benefits, particularly in how arrangements relating to the default of a clearing member
would operate. We are supporting initiatives to make those facilities available.
4.16 Dealers have agreed with the international group of supervisors, including the FSA,
that they will have facilities available for buy-side access to CDS clearing, including
segregation and portability. The dealers and CCPs are working together to achieve
this and regulators are actively monitoring progress against these commitments.7
4.18 If non-financial firms were forced to clear products, the requirement to post both
initial and variation margin to the clearing house or their clearing member would
increase costs and introduce an unpredictable liquidity burden. In order to meet
their liquidity needs, it is likely non-financials would be dependent on financial firms
extending them credit which would then transfer the counterparty risk back to the
financial sector rather than mitigating it.
7 http://www.newyorkfed.org/newsevents/news/markets/2009/060209letter.pdf
4.20 Whilst the UK Authorities fully appreciate that the main objective of any new
derivatives risk management system is to identify and mitigate systemic risks,
individual PFI special purpose companies are unlikely to be as systemically
important as a major bank.
Preferred approach
4.21 The introduction of CCP clearing is focussed on mitigating the systemic shock that the
failure of a major participant would bring about. As set out in the Turner Review9
regulators can not be indifferent to the risks posed by non-financial firms and as such
a blanket carve-out from the requirements to mitigate counter-party risk within the
financial system does not seem appropriate. All market participants should expect to
bear the cost of mitigating their counterparty risk within the system.
4.22 We are of the view that financial firms should use clearing services for
clearing-eligible products. Where the entity is not a financial firm or the product
is not clearing eligible, firms should as far as possible use bilateral collateralisation
to mitigate their counterparty risk. However, if operational or financial resources
do not permit this, then firms should expect to be charged by their financial
counterparty the cost of the appropriate capital charge under the CRD as a
means of mitigating their counterparty risk.
4.24 The UK has been leading the call for a Clearing Directive in Europe. We therefore
welcome the Commission’s proposal for legislation to establish a regulatory framework
for CCPs. We believe this should lay down uniform high regulatory standards and
enshrine fair and open cross-border access for, and competition between, clearing
houses. These standards should align with those to be agreed by CPSS-IOSCO
(outlined below).
8 Such companies generally construct and operate infrastructure assets on behalf of public sector clients, raising the
required finance (often LIBOR-based floating rate loans) on the back of long-term concession agreements which are
predicated on fixed interest rates.
9 http://www.fsa.gov.uk/pubs/discussion/dp09_02.pdf
4.26 It is important to bear in mind that in the most extreme circumstances, default of
several of a CCP’s members could result in the failure of the CCP itself. As CCPs will
be increasing in systemic importance, a failure brings with it the possibility that public
authorities would need to step in to provide support, for example acting as lenders of
last resort in order to support CCPs during a temporary liquidity problem. An insolvent
CCP could impose a direct cost for taxpayers of the home state. It has already been
recognised that supervisory responsibility for financial institutions which ultimately may
need the taxpayer to stand behind them should reside with the home state.
4.27 As the Commission or a pan European regulatory authority cannot bear the fiscal
responsibility in the event of a failure of a CCP, full supervisory responsibility should
therefore reside with the home state.
4.29 At the European level, ESCB and CESR have agreed recommendations based on the
work of CPSS-IOSCO to include provisions for OTC derivatives. While these
recommendations are non-binding, the members of ESCB and CESR have committed to
promote and monitor the application of the Recommendations within their jurisdictions.
Proposed solution
4.30 There should be a market shift towards greater CCP clearing of OTC derivatives.
The use of ambitious and challenging targets for CCP usage for clearing eligible
products by appropriate clearing members with close regulatory oversight is in the
first instance helping to achieve this objective and this approach should be continued.
In addition, we need to consider the extent to which regulatory intervention may be
required to drive more of the market to CCP clearing and how these requirements
should apply to non-financial firms. The regulation of CCPs should be reinforced by
a robust regulatory framework with home state regulators retaining authority for the
authorisation and on-going supervision of CCPs. There should be strengthened global
prudential and operational standards for CCPs and these should be reflected in any
European legislation.
The issue
5.1 CCP clearing can be effective in reducing counterparty risk, but due to the variable
liquidity of different products within the OTC derivatives market and the legitimate
need to access bespoke products, only a proportion of the overall derivatives market
will ever be suitable for CCP clearing.
5.2 Where CCP clearing is not available or not used, it is important the two counterparties
bilaterally manage their counterparty risk. The near-collapse of AIG is an example
where commercial decisions regarding these bilateral arrangements resulted in
incomplete mitigation of the counterparty risk. It is therefore essential that steps
are taken to ensure that these types of transactions are adequately risk managed.
Market participants and regulators should be able to take comfort that in the event
of a default of a major market counterparty the contingent exposures have been
appropriately collateralised and/or capitalised.
Existing framework
5.3 A legally robust and well-understood framework is already provided by ISDA. It
includes a netting agreement (an ISDA Master Agreement) which reduces the portfolio
of exposures to one net exposure between the two counterparties and the Credit
Support Annex/Deed (CSA/CSD). The latter details the arrangements by which the
parties post collateral to each other to cover the out-of the-money exposure should
either counterparty default.
5.5 For example, under existing bilateral arrangements some of the issues below can arise:
• As there is a time lag between market moves and the posting of collateral, it is
possible unexpected unsecured exposures may arise during volatile markets.
• On some occasions it is possible that the out-of the-money party may post collateral
to the other party in excess of the amount the market value of their potential
• Commercial interests to attract and retain business may influence firms into
weakening the provisions of the standard form of the collateralisation agreements
resulting in increased retained risk.
• Unresolved disputes between the two parties may result in insufficient collateral
being posted and incomplete mitigation of counterparty risk.
UK position
5.8 The UK Authorities welcome the European Commission’s recognition of the weaknesses
in the current model. However, in our view its proposals for mandatory posting of
initial and variation margin may not fully address all of the risks inherent in the
existing arrangements. In addition, they may have negative consequences for firms,
especially non-financial firms who might find it difficult to risk manage the unpredictable
liquidity burden this would impose and potentially exacerbate existing risks associated
with over-collateralisation.
Preferred approach
5.11 The UK Authorities view CCP clearing as a lower risk method of mitigating
counterparty risk and therefore, in accordance with the G20 communiqué, we support
higher capital charges for non-cleared counterparty risk. The UK Authorities would
like to see risk-proportionate capital charges being applied to bilateral counterparty
exposures in order to motivate firms to adopt the identified best practices associated
with bilateral collateralisation arrangements.
5.12 Financial firms should use CCP clearing for very significant levels of clearing-eligible
products. For non-financial firms or where the product is not clearing eligible, firms
should as far as possible use bilateral collateralisation to mitigate their counterparty
risk. However, as outlined in Chapter 4, the non-financial sector is likely to have
significant difficulties managing the liquidity risk of collateralising daily marked to
market valuations. In such cases bilateral collateralisation may not be a proportionate
risk mitigant and these firms could expect to be charged by their financial counterparty
the appropriate capital charge under the CRD as a means of mitigating their
counterparty risk.
5.13 In our view, regulators need to consider the whole bilateral collateral process and
market practices associated with it and how these vary across different market sectors
and geographic regions to determine if they meet the required high standards for risk
mitigation rather than a narrow focus on the amount of margin being posted.
5.14 The UK Authorities have asked market participants, including dealers, buy-side firms
and corporates, to undertake a fundamental review of current bilateral processes with
the goal of enhancing the robustness of the current processes, practices and/or
infrastructure. Key deliverables are:
• a report in January 2010 which will provide regulators and policy makers with
details on how the existing processes function, identifying risk and proposing
the most effective method for strengthening risk management procedures for
non-CCP cleared transactions.
5.15 We look to the Commission and other policy makers to take into account the
conclusions of this review before drafting legislation in this area in order to fully
address the risks in current processes.
The issue
6.1 Regulatory capital is a key tool in mitigating prudential and systemic risks; many
key requirements are being reviewed. It is important to set capital requirements to
reflect the relevant risks; which ought to also serve to appropriately incentivise the
use of CCP clearing.
Current position
6.2 Firms subject to the FSA Prudential Sourcebook for Banks, Building Societies and
Investment Firms (BIPRU) are generally required to hold capital against the risk that
their counterparty defaults. However, exposures to a qualifying central counterparty,
with the exception of a default fund contribution, do not currently attract a capital
charge. This reflects a desire amongst policy makers internationally to incentivise the
use of central clearing as opposed to bilateral OTC arrangements, given a perception
that central clearing reduces counterparty risk. At the time when Basel II came into
force, it had been agreed that CCP exposures should attract a 0% capital requirement.
6.3 Despite the capital concession, what we have seen amongst regulated firms is a
preference in some OTC derivative markets for bilateral agreements as opposed
to using a CCP. This might suggest that the current capital requirements have not
delivered a sufficient incentive to use CCP clearing, although other factors are
likely to be significant.
6.4 The predominant view amongst international regulatory bodies remains that for those
products which are clearing-eligible, central clearing, with appropriate oversight, is
preferable to the bilateral alternative. The desire then to incentivise the use of CCPs
has not diminished, and continues to dominate the international agenda with capital
charges for both centrally cleared and bilateral trades currently being discussed under
the Basel framework.
6.7 Exposure to a well-managed and well-capitalised CCP, should by virtue of its low
risk, attract a lower capital charge. Given the mechanics of a CCP default, it must
hold that the default of a CCP is less probable than the default of an individual
member. Therefore a lower capital requirement for a CCP relative to an OTC
exposure is wholly consistent with a risk-based and proportionate approach.
6.8 It is also important to consider that the introduction of a CCP may provide some
additional system-wide benefit by acting as a circuit breaker to systemic risk on a
major participant’s failure. Since this would not be reflected in individual, firm-level
capital requirements, a capital concession to reflect this reduction in systemic risk
may therefore be optimal.
6.9 That said we believe it is important to consider the tiering of the CCP’s capital
structure when evaluating the relative risk of different classes of exposure. It is
an oversimplification to assume all exposures to a CCP are equal and any capital
requirement must acknowledge this heterogeneity and differentiate between exposures
whose probability of loss is materially different.
6.10 Contributions to the default fund are intended to cover losses given the default of
other clearing members. Given a CCP will exhaust its default fund before it draws
on its own capital, the probability of the default fund suffering a loss is substantially
higher than the default of the CCP and we consider it appropriate that exposures to
the default fund receive a higher capital charge, relative to other exposures.
6.11 From a macro-prudential perspective, higher capital charges against holdings of capital
in other financial institutions are also desirable in order to limit ‘double gearing’ in
the financial system. In line with this, current BIPRU rules exempt default fund
contributions from a general capital concession in which all other CCP exposures
receive a zero capital charge. Instead, we believe contributions to the default fund
should be risk weighted like any other exposure in accordance with the relevant
BIPRU rules.
6.14 We support the use of clearing where products can be appropriately managed.
However, we are concerned that using disproportionately penal OTC capital
requirements to broadly incentivise central clearing could force a significant volume
of products, where robust risk management practices have yet to be developed, onto
a clearing house. This would centralise systemic risk and could jeopardise market
integrity. We would therefore not support proposals to incentivise the use of clearing
via the use of penal capital charges. By the same logic, we do not support proposals
that argue for mandating the use of CCPs.
6.16 Regarding the likely future capital regime for CCPs, the current view of the Basel
working group is that the prudential treatment may be revised to better reflect the
true prudential risk of transacting with a CCP. This work is ongoing and the FSA
will continue to input into the international discussions.
6.17 The PDG has also tasked the Trading Book Group (TBG) to undertake a fundamental
review of trading activities. This work will involve consideration of the appropriate
capital requirements for all trading activities.
6.18 The current capital framework for trading activities is focused on the market risk of
a product, with counterparty risk considered for OTC derivatives. Aside from the
prudent valuation requirements, the current market risk framework makes no explicit
distinction between centrally cleared and bilateral trades. In the future it is possible
that market risk requirements will give explicit recognition to factors such as the
liquidity and price transparency of derivative contracts. Such considerations would
clearly have implications for OTC derivatives markets.
7.1 Reducing counterparty risk is not the sole focus of regulatory reforms. The financial
crisis has also brought to light many weaknesses in OTC derivative the markets which
relate to their opaque nature. The UK Authorities share the view that measures designed
to improve the transparency of these markets – both in terms of the information
provided to market participants and the information provided to regulators – can
deliver a range of efficiency and risk benefits and should be a key objective of the
proposed financial reforms.
The issue
7.2 One of the key weaknesses during the financial crisis was a lack of information
providing regulators with a clear aggregate picture of the interconnectedness
of positions held by the firms they supervise and their potential exposures to
market counterparties.
Regulatory solution
7.3 Providing position transparency to regulators via the use of a trade repository
would help identify potential sources of concentration risk and market instability
and would support financial stability planning. Information from trade repositories
can be used by regulators to assess risks on the books of their regulated entities, and
could enable the market as a whole to identify aggregated risks for specific asset classes.
This is in line with the G20 communiqué, which requires the registration of all OTC
derivative trades in a trade repository.
7.4 We welcome the industry’s efforts to establish and use trade repositories for CDS,
interest rate derivatives and equity derivatives. We are encouraged by the industry’s
commitment targets for trade repository usage and acknowledge the progress which
has already been made.10 We also welcome discussions regarding the establishment
of trade repositories for other asset classes.
10 http://www.newyorkfed.org/newsevents/news/markets/2009/060209letter.pdf
7.6 We are also conscious that the use of more than one trade repository for any asset
class would result in data fragmentation. The ways of aggregating data from a variety
of sources, and the costs, need to be carefully considered in order to minimise the
resources expended by regulators. A single trade repository per asset class would avoid
this problem but may create monopolistic risks that would need to be managed.
7.7 We support the Commission’s position that European regulators must have access to
relevant global information. But we do not think that this should mean that specific
repositories need to be set up in Europe, if there are adequate repositories already
elsewhere. We support location-neutral policies with regards to the establishment of
such central data repositories providing they are supported by internationally agreed
information sharing arrangements.
7.9 Whilst trade repositories will require some regulatory framework, in our view this
should be reasonably high-level in approach, with provisions relating to areas including
the legal basis, operational resilience, access criteria and transparency. A pan-European
regulator is not necessarily needed to deliver this. In this context both the CPSS-IOSCO
Working Group and CESR have established workstreams aimed at defining a broad
set of requirements for trade data repositories. We are engaged in these efforts and
are supportive of this work. It is anticipated that the work in the separate forums
will be finalised in the first half of 2010. We would highlight the need to avoid
duplication of these efforts.
7.10 Furthermore, we would highlight the new supervisory model being developed under
the ORF for DTCC, the trade repository for CDS, whereby home state regulation is
supplemented by a network of supervisors to ensure the information needs of global
regulators are met. Further consideration should be given to how this might apply to
other trade repositories.
7.11 We need a framework which supports the sharing of relevant information between
the appropriate authorities to enable them to fulfil their regulatory responsibilities.
The ORF is the best international forum to achieve this and work is already in hand
to deliver this.
7.13 In the UK, the FSA’s Service Company regime provides the necessary flexibility
to provide a regulatory umbrella for trade repositories in the UK. The regime applies
basic requirements with regard to systems and controls, governance, financial
requirements and record keeping. However, it also gives the flexibility to strengthen
standards to accommodate international and entity specific requirements where
appropriate such as access, transparency and reporting.
7.15 This reporting would be made available to relevant authorities depending on their
regulatory remit. It should be noted that these arrangements are not designed to
supersede authorities’ existing information-seeking arrangements or powers, including
where information is sought directly from infrastructure or market participants.
Challenges
7.16 The current focus of regulators is on the registration of trades which have not been
cleared by a CCP but ultimately regulators will need to have access to the complete
picture of activity of the entities which they supervise. This could be achieved in a
number of ways. For example:
• by requiring firms to register CCP cleared trades directly with the trade repository;
• for the relevant CCPs to submit a data feed directly to the repository; and
• or for regulators to obtain the data for cleared trades from CCPs directly and
then to aggregate the data themselves.
7.17 Further work on this issue is needed and appropriate consideration should be given
to the cost associated with each option.
7.18 Regulators are closely working with the industry and through fora such as ISDA to
identify any potential difficulties in reporting trade data. One particular issue already
highlighted concerns the confidentiality of reporting to a third party service provider
and the subsequent use of that data. A legal assessment is currently being undertaken
to further understand these difficulties. Initial indications are that there will be many
legal obstacles to overcome in order to facilitate the legal registration of trades from
participants in all jurisdictions.
The issue
7.19 In Europe there are no harmonised requirements for transaction reporting of all
OTC derivatives. This may hamper the ability of regulators to detect market abuse.
UK Approach
7.20 In the UK OTC securities derivatives, such as contracts for difference (CFDs) and
CDS, where their underlying instruments are admitted to trading on a regulated or
prescribed market, are subject to the FSA transaction reporting regime. This is because
there is evidence that the use of derivative contracts can be used to manipulate the
price or exploit inside information of the underlying securities which are within scope
of our Market Abuse regime. We support the extension of transaction reports of
OTC securities derivatives by Member States who do not currently collect this
information as this will enable more effective market monitoring across Europe.
Work is in hand through CESR to achieve this.
7.21 The FSA does not require transaction reporting for other OTC non-securities
derivatives such as interest rates, commodities and foreign exchange.
• The degree to which the participants in each sector are regulated. For example
many market participants are not MiFID investment firms.
• The degree to which the sectors are influenced by non-EEA entities as this will
affect how complete the data will be. We know there is a strong international
dimension to commodity markets.
• The degree to which the sectors are influenced by asset types we can control.
The issue
7.23 OTC derivative markets are not subject to formal pre and post trade transparency
requirements. As a result some market participants have better access to better
information on prices and volumes which can lead to an unfair advantage in terms
of the price formation process.
7.25 In the Turner Review and accompanying DP09/0211 the FSA set out a proposed
framework for calibrating post-trade transparency regimes. It is essential that any
regime is structured so as minimise the scope for a negative impact on liquidity due
to an unwillingness of market participants to trade. We recommend that the following
factors are taken into consideration:
Market participants
7.26 The need for transparency differs across markets and classes of market participants.
Some OTC derivative markets have a higher degree of inter-dealer participants (such
as CDS) who often have access to greater information on traded prices and volumes.
Others are characterised by higher investor participation (such as interest rate and
foreign exchange derivatives) who tend to have access to less information. Increasingly
these latter types of participants are expressing the need for better access to greater
information. To better inform our view the FSA will undertake work to gain a clear
oversight of the range of participants per asset class in question.
Market liquidity
7.27 A certain degree of market liquidity is needed in order to absorb the possible impacts
of introducing a post-trade transparency regime. We need to avoid a situation where
in publishing information on traded prices and volumes, participants become reluctant
to commit capital and in turn withdraw liquidity from the market.
11 http://www.fsa.gov.uk/pubs/discussion/dp09_02.pdf
Existing infrastructure
7.30 Any post-trade transparency regime should be delivered in the most cost-effective way.
We should therefore look to existing infrastructure, for example data vendors, CCPs,
trade repositories, to see how these can facilitate the delivery of timely post-trade
information to market participants.
7.31 Taking the above factors into consideration it is therefore likely that any post-trade
transparency regime will vary on an asset class by asset class basis.
7.33 Given the structure of European derivative markets and how they differ to
equity markets, careful consideration will need to be given to how such a regime
is implemented and how to ensure data accuracy.
7.36 The UK Authorities support this and a similar framework for interest rate derivative
reporting is currently being developed.
Pre-trade transparency
7.37 There has been little work to date regarding the need and benefits of extending
pre-trade transparency requirements to assets other than shares. Some market
participants, including some non-financial firms, are of the view that they generally
have good access to accurate pre-trade information. Many market participants are of
the view that post-trade pricing information is a more valuable source of information.
This is particularly the case for bespoke products. The added dimension of on OTC
trading framework can provide a challenge for introducing pre-trade transparency
requirements. Further work is therefore needed and we would encourage the
Commission to undertake a thorough analysis of pre-trade transparency related
issues before designing a legislative framework.
The issue
8.1 The liquidity of financial markets was severely impaired during the crisis with heightened
concerns over counterparty risk resulting in an unwillingness of some participants to
trade. For many participants wishing to trade not only did they struggle to find a willing
counterparty, there was also an absence of price transparency which hindered the price
formation process and valuation of existing positions.
Possible solutions
8.2 Trading through organised trading platforms provides regulators with transparency of
trading and market conduct, and can provide market participants with a centralised
pool of liquidity – tradable through a transparent central orderbook under standardised
terms and conditions and predominantly cleared through a CCP. So regulated trading
venues might appear to be attractive solutions to opaque and complex trading on
OTC markets.
8.3 However, mandating trading on organised markets would prove detrimental as:
ii. It would severely impact some of the OTC market, as there is insufficient
liquidity in some contracts to sustain trading on organised markets.
The issue
9.1 In commodity markets the regulatory debate has been focused on two discrete issues:
9.2 The first issue is a regulatory objective of the UK Authorities, whereas the second
issue is not as it falls outside the current remit of the FSA (as defined by legislation).
As the debate has unfolded the two distinct issues have often not been separated.
However it is important to retain clarity of distinction between the two issues and
to be clear about whether or not the issues being discussed relate to a current
regulatory objective.
9.4 However, we are of the view that the regulatory focus should be on preventing
manipulation by every type of market participant rather than on particular types
of market participant. We do not believe, nor have we seen evidence, that a blanket
approach through specific position limits is necessarily the most effective way to
monitor, detect and deter manipulative behaviour in derivative markets, whether
they are on exchange or OTC.
9.6 Whilst not opposed to the principle of regulators having the option of formal position
limit setting powers in relation to combating manipulation for OTC markets, we do
have concerns about the possible consequences. It is essential that any policy measures
be carefully and sensibly calibrated and consistently applied and we encourage the
Commission to undertake a robust impact analysis on this issue.
9.8 There are two main regulatory methods for preventing manipulation arising from
large positions. Firstly the use of position and accountability limits, or secondly a
more encompassing set of regulatory tools with an emphasis on a broad position
management approach. The UK regime adopts the latter approach. (See paragraphs
9.12 to 9.15).
Position limits
9.9 Position limits were originally imposed in exchange-traded commodity derivative
markets as a tool for ensuring that large positions were not amassed as the expiry of a
physically delivered contract approached. There are two principal aims of this approach.
Firstly, limiting concentrated and dominant positions reduces the risk of a “market
squeeze”.13 Secondly, limits assist in maintaining market confidence and integrity by
preventing participants from incurring obligations to accept or deliver large quantities
of physical commodities where they are not equipped to do so. These limits may be
set by regulators or by the exchanges on which the contracts are traded, depending
on the contract and the regulatory regime in question.
9.10 Given their origins in the commodity markets, a position limit regime must
recognise the need for certain “commercial” traders to hold large positions at given
points in a contract life, in order to allow effective hedging of underlying price risk.
An exemption-based position limit regime therefore comes with potential execution
issues that would need to be carefully managed. Such an approach may pose significant
administrative and logistical burdens in ensuring equality of treatment amongst all
participants. There is also a cost in setting, monitoring and enforcing against limits
in order for them to remain effective and credible.
13 A market squeeze in a derivatives market may occur when market shorts are artificially inhibited from obtaining a
physical commodity to meet delivery obligations as a result of a controlling interest in that underlying commodity,
and are thereby forced to close out their positions at grossly inflated prices.
9.13 The UK regime does not require exchanges to impose position limits on their markets.
Rather, in order to satisfy the requirement to operate markets which are fair and
orderly at all times, all UK exchanges have incorporated broader position management
powers into their rules.
9.14 Members of UK exchanges are required to abide by the position reporting requirements
as set out in the rules of the exchange. These rules also give the exchanges authority
to manage positions at any time throughout a contract’s life cycle and to instruct a
member to close or reduce a position with the exchange, if that is necessary, to secure
fair and orderly markets. If the member does not comply, the exchange has the power
to close the position unilaterally.
9.15 A position management approach such as the UK’s takes account of contract liquidity
as well as the scale and nature of participants involved at any given point in time; this
is not necessarily the case with a position limit regime.
9.17 The UK Authorities do not consider that precluding, or limiting, financial participants
as a group in UK commodity, or broader derivative, markets would necessarily reduce
the potential for manipulation. Moving away from a regime which is flexible and
established, to a different and more rigid system would imply there is an identifiable
problem with the current regime. We have seen no evidence of this.
Non-Commercial Participants
9.20 Over the last two years, certain commentators and market observers have linked the
growth in financial, or “speculative”, participation in commodity markets with recent
significant price movements, particularly in oil. We recognise that this type of investor
has impacted the nature of commodities markets as a whole, for example, as a result
of different methods of trading and increased volumes.
9.21 However, the majority of academic studies and evidence do not support the proposition
that prices have been systematically driven by this increased inflow of financial interest.
Indeed the majority of commentators have concluded that commodity price movements
cannot be solely attributed to the activities of any one class of investor and are
principally attributable to market wide factors. We agree with these conclusions.
9.23 We also consider that limiting financial participation more generally would hamper
market efficiency. To use oil markets as an example, increased participation has
brought significant benefits, such as greater depth and liquidity. In particular we
9.24 To restrict participation to producers and end-users, and to exclude, or even limit,
financial players would, in the view of the UK Authorities, be unlikely to have a
controlling effect on market prices, and potentially be detrimental to efficient markets
and the price formation process in general.
Proposed Approach
9.25 The UK Authorities would urge caution in the application of any specific position limit
power, and the expectation that these regulatory tools might achieve the objective of
reduced price volatility, or manipulation, as there appears to be no conclusive evidence
that this may be the case. We also call on legislators to give careful consideration to the
broader possible consequences of introducing a position limits regime. In our view a
broader position management approach which does not focus on one type of participant
is the most effective approach to ensuring market integrity in derivative markets.
10.1 Policymakers and legislators on both sides of the Atlantic are currently deliberating
a comprehensive set of proposals which are designed to support more robust,
efficient and transparent derivative markets. It is important that the overall package
of policy measures are deigned so as to most effectively address systemic risk and
transparency issues.
10.2 As outlined in this paper the UK Authorities support drives towards greater
standardisation but note that the degree of standardisation is not the only criterion to
consider when determining whether a product should be cleared. Instead we strongly
support the use of central clearing for clearing eligible derivatives through robustly
managed clearing houses that meet a uniform set of high standards. These should be
further supported by effective supervision by home state regulators. Trades which
are not centrally cleared should be subject to robust bilateral collateralisation processes
and/or the appropriate risk-proportionate capital charge.
10.3 We support the registration of all OTC derivative transactions in a trade repository
with further transparency provided to the market through sensibly calibrated
transparency requirements.
10.4 Once these proposals have achieved their intended outcome it is unclear at this stage
what benefits forcing trade flow through organised trading platforms would deliver.
We urge legislators on both sides of the Atlantic to approach this regulatory tool with
caution as regulatory objectives can be achieved by other means. Indeed once current
proposals are implemented and have had the opportunity to bed down we can expect
market forces to move more trading activity through these types of trading venues.
10.5 As we have outlined the current broad position management approach adopted
in the UK is effective in combating market manipulation and so we see no need to
introduce position limits for this purpose. With regards to controlling or limiting
price movement we have not seen evidence that a position limits regime is needed.
10.6 As highlighted throughout this paper there is a very significant amount of work
underway within the international regulatory community and in partnership with
the industry. It is essential that legislators do not pre-judge the outcome of these
pieces of work; that careful consideration is given to this work when defining
legislation; and that there is not an unnecessary duplication of efforts.
10.8 These work streams can be expected to evolve as regulatory engagement increases.
In order to achieve the appropriate sequence of outcomes it is important that
prioritisation is discussed and agreed amongst relevant stakeholders in order
to ensure the most effective deployment of resources.
10.9 But whilst significant strides have been made within these fora more still needs to
be done. We are encouraged by the commitment shown by the industry to support
change so far and we ask that sufficient momentum and resourcing is maintained.
10.10 As further detail of the package for regulatory change emerges we look forward to
working with our colleagues across the globe to ensure that an internationally consistent
set of definitions and outcomes are achieved so as to maximise the impact of these
historic reforms.
Annex 1 1
OMG Operations Management Group
2 Annex 1
Annex 2
Overview of international
regulatory workstreams
Annex 2 1
Geographic Forum Workstream / Content Detail
Relevance
International OTC Regulators Forum to discuss http://www.newyorkfed.org/newsevents/
Derivatives developments on OTC derivatives news/markets/2009/ma090219.html
Regulator clearing initiatives and trade
Forum (ORF) repositories.
Five dedicated working groups have
been set up:
1. Information needs for market
regulators
2. Prioritisation of additional data
reporting items
3. ‘Business purpose’ information
4. Data reporting formats, delivery
mechanisms, aggregation
5. Data reporting for rates repository
2 Annex 2
Annex 3
Across the three existing clearing houses, the products eligible to be cleared by these
entities are currently the liquid indices – namely High Yield, HiVol and Crossover for
both CDX and ITraxx – and a handful of single names. We expect to see this product
set widen in the near future to include the single names contracts for the constituents
of the indices already being cleared. The G15 banks have committed to clear 80% of
these products from October 2009. Good progress is being made against these
targets but momentum needs to be maintained.. Regulators will actively monitor
progress against these targets and take steps to address any failures. The clearing
target level will apply automatically as the product set expands.
However, this will still leave a large proportion of both the index (tranched and
untranched) and single name population which are at this stage unclearable. There are
challenges to expanding the products available to be cleared as liquidity and price
transparency are important factors in being able to build a robust risk management
process necessary for a clearing house. There may also be further challenges ahead in
standardising the products, such as tranched indices, so as to reduce the operational
risk to clearing houses.
LCH.Clearnet Ltd operates a clearing service for interest rate swaps with indications
that it clears over 60% of the global interest rate swaps market. As at the end of
Annex 3 1
September 2009, LCH.Clearnet Ltd held open interest of over 3200 trillion in
SwapClear contracts. LCH.Clearnet Ltd also provides clearing services for OTC
commodity derivates contracts. Although these commodity contracts have won
some market support their volumes are significantly lower than for LCH’s swaps
products, reflecting the differing nature of the underlying market.
In addition to the OTC CDS products noted above, ICE Clear Europe clears OTC
energy products traded through the global OTC trading venue operated by ICE group.
These products include oil, gas and electricity contracts.
CME provides a clearing service for over 700 commodity contracts through its ClearPort
OTC clearing service. These contracts include metals, energy, and agricultural products
and have average daily volumes of over 700,000 contracts. CME has also applied for
recognition from the FSA and intends to launch a European clearing house within
the next six months. They plan to make OTC CDS products available through this
clearing house.
CME plans to accept FX contracts for clearing through ClearPort by the end of 2009.
Other clearing houses have expressed interest in also providing clearing services for
OTC FX products, but none has announced firm plans to launch such a clearing service.
This lack of progression towards service provision is likely to be largely a result of
a perceived lack of appetite for central counterparty services amongst FX market
participants, rather than any specific operational or legal challenges presented by
the FX market.
2 Annex 3
The Financial Services Authority
25 The North Colonnade Canary Wharf London E14 5HS
Telephone: +44 (0)20 7066 1000 Fax: +44 (0)20 7066 1099
Website: http://www.fsa.gov.uk
Registered as a Limited Company in England and Wales No. 1920623. Registered Office as above.